Loading
Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.
Direct links plus the targets, companies, and technologies of this cancer's products.
Shares HER2-low eligibility for trastuzumab deruxtecan, and TROP2 ADCs without a test (triple-negative disease), TROPION-Breast02, HER2-low (IHC 1+ or IHC 2+/ISH-negative), ASCENT and the tag subtype-page.
Shares Ipatasertib, EMBRACA, OlympiAD, Talazoparib and the tag subtype-page.
Shares Sacituzumab govitecan, Olaparib, Trastuzumab deruxtecan, Capecitabine and the tag subtype-page.
Shares Sacituzumab tirumotecan, Olaparib, Trastuzumab deruxtecan, Durvalumab and the tag subtype-page.
Shares Sacituzumab tirumotecan, Atezolizumab, Trastuzumab deruxtecan, Gemcitabine and the tag subtype-page.
Shares Sacituzumab tirumotecan, Olaparib, Trastuzumab deruxtecan, Paclitaxel / nab-paclitaxel and the tag subtype-page.
Shares PD-L1 CPS (combined positive score), Combined positive score (CPS), Durvalumab, Paclitaxel / nab-paclitaxel and the tag subtype-page.
Shares PD-L1 CPS (combined positive score), Trastuzumab deruxtecan, Capecitabine, Paclitaxel / nab-paclitaxel and the tag subtype-page.
The same record for scripts and assistants; checked 2026-09-17. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.